Wells Fargo Maintains Equal-Weight on Apellis Pharmaceuticals, Lowers Price Target to $26

Benzinga · 4d ago
Wells Fargo analyst Derek Archila maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Equal-Weight and lowers the price target from $30 to $26.